Aim: Numerous chronic diseases exhibit multifactorial etiologies, so focusing on a single therapeutic target is usually an inadequate treatment; instead, multi-target drugs are preferred. Herein, a panel of phenolic thioureas and selenoureas were designed as new prototypes against multifactorial diseases concerning antioxidation and cytotoxicity, as a pro-oxidant environment is usually found in such diseases.
Results: Selenoureas were excellent antiradical agents and biomimetic catalysts of glutathione peroxidase for the scavenging of HO. They were also potent and selective cytotoxic agents against cancer cells, in particular HeLa (IC 2.77-6.13 μM), apoptosis being involved. Selenoureas also reduced oxidative stress in HeLa cells (IC= 3.76 μM).
Conclusion: Phenolic selenoureas are promising lead structures for the development of drugs targeting multifactorial diseases like cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/fmc-2016-0139 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors.
Eur Thyroid J
January 2025
D Yabe, Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine Faculty of Medicine, Kyoto, Japan.
Immune checkpoint inhibitors (ICIs) frequently cause immune-related adverse events (irAEs), with thyroid irAEs being the most common endocrine-related irAEs. The incidence of overt thyroid irAEs ranged 8.9-22.
View Article and Find Full Text PDFDecoupling Individual Host Response and Immune Cell Engager Cytotoxic Potency.
ACS Nano
January 2025
Aix-Marseille Univ., CNRS, INSERM, LAI, Centuri Living Systems, 13009 Marseille, France.
Immune cell engagers are molecular agents, usually antibody-based constructs, engineered to recruit immune cells against cancer cells and kill them. They are versatile and powerful tools for cancer immunotherapy. Despite the multiplication of engagers tested and accepted in the clinic, how molecular and cellular parameters influence their actions is poorly understood.
View Article and Find Full Text PDFInvestigations Reveals Potential Cytotoxic Activity of Fermentation Metabolites from Actinomycetes Isolated from Lonar Soda Lake Against HeLa Cancer Cell Lines.
Curr Protein Pept Sci
January 2025
Department of Pharmacognosy, SVKM's NMIMS, School of Pharmacy & Technology Management, Hyderabad, Telangana- 509 301, India.
Background: Actinomycetes, Gram-positive bacteria, are recognized for producing bioactive metabolites. Lonar Soda Lake, an alkaline ecosystem, hosts diverse actinomycetes with possible anticancer activities.
Aim: To assess the cytotoxic potential of fermentation metabolites from actinomycetes isolated from Lonar Soda Lake against HeLa cancer cells employing and methods.
Scientific investigation on antibacterial, antioxidant, cytotoxic effects and TLC bioautography of stem bark extracts.
J Complement Integr Med
January 2025
PKFokam Institute of Excellence, Yaoundé, Cameroon.
Objectives: Hochst, belonging to the family, is known for its ethnomedicinal values, particularly in treating various diseases in Africa. This study aimed to investigate the antibacterial, antioxidant, and cytotoxic properties of stem bark extracts, with a specific focus on assessing their bioactive potential and identifying active compounds via TLC bioautography.
Methods: The antimicrobial activity was assessed using the agar well diffusion method against selected clinical strains.
EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells.
Sci Rep
January 2025
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Antibody-drug conjugates (ADCs) are an emerging strategy in cancer therapy, enhancing precision and efficacy by linking targeted antibodies to potent cytotoxic agents. This study introduces a novel ADC that combines ribonuclease A (RNase A) with cetuximab (Cet), an anti-EGFR monoclonal antibody, through a polyethylene glycol (PEG) linker (RN-PEG-Cet), aimed to induce apoptosis in KRAS mutant colorectal cancer (CRC) via a ROS-mediated pathway. RN-PEG-Cet was successfully synthesized and characterized for its physicochemical properties, retaining full enzymatic activity in RNA degradation and high binding affinity to EGFR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!